Search
OPC-51803
go.drugbank.com/drugs/DB05838ExperimentalIt is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence. … It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states.
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalThe QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems[L30628]. … It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].
R1204
go.drugbank.com/drugs/DB05118ExperimentalR1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Tasquinimod
go.drugbank.com/drugs/DB05861InvestigationalThe quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts
SVV-001
go.drugbank.com/drugs/DB06129InvestigationalSVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. … SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in
Atibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
ChulaCov19 mRNA vaccine
go.drugbank.com/drugs/DB16445ExperimentalThe ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678]. … Pre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies[L30678].
Puromycin
go.drugbank.com/drugs/DB08437ExperimentalPuromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. … Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.
RO7296682
go.drugbank.com/drugs/DB17531InvestigationalRO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. … RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T<sub>reg</sub>) cells.
Luveltamab tazevibulin
go.drugbank.com/drugs/DB17563Investigational[A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer